/ Print /

Pharmacy Strategy

Top solutions to lower drug pricesPBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.
Trump declares Opioid ‘National Emergency’: 3 healthcare impactsExperts share how the declaration could affect how the opioid epidemic is managed.
Controversy surrounds Exondys 51 approval: What to knowNew medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
Brace for a barrage of biosimilarsThe next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
Three reasons for nonadherenceUncover the root causes of why patients become nonadherent and be better positioned to improve the lives of patients and reduce costs through improved health outcomes.
ICER, VA join to work on drug value, price negotiationsAnalysts discuss how pharmacoeconomics will make a difference in treatment decisions.
Clinical pharmacists gain prominence as the industry changes
Clinical pharmacists gain prominence as the industry changesPayers realize value in partnering with pharmacists to manage medication-related complications
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
Six barriers to prescribing PCSK9 inhibitorsA National Lipid Association survey has interesting findings on the prescription approval process for PCSK9 inhibitors.